79013-29-9

Upstream product

• 5464-11-9 2-methylthio-2-imidazoline hydroiodide 
• 140-75-0 para-fluorobenzylamine 

Downstream Products

• 68020-59-7 7-amino-8-(4-fluoro-benzyl)-6-nitroso-2,8-dihydro-3H-imidazo[1,2-a]pyrimidin-5-one 
• 68020-75-7 4-(4-fluoro-benzyl)-1⁽³⁾,4,6,7-tetrahydro-imidazo[1,2-a]purin-9-one 
• 68020-66-6 4-<(4-fluorophenyl)methyl>-6,7-dihydro-3H-imidazo<2',1':5,6>-υ-triazolo<4,5-d>pyrimidin-9(4H)-one 

Relevant academic research and scientific papers

Substituted 6,7-dihydroimidazo[1,2-al]purin-9 (4H)-ones

The synthesis of a series of substituted 6,7-dihydroimidazo[1,2-a]purin-9(4H)-ones is described. Several members of the series exhibit enhanced antiallergic and bronchodilator activity and reduced side effects as compared to theophylline. Structure-activity relationships and metabolic considerations are discussed for the series. Analogues substituted with a 4-(4-chlorobenzyl) moiety, such as 33 and 40, show an optimal balance of antiallergic and bronchodilator activity and are of particular interest. Compound 33 is significantly more potent than theophylline against both metacholine- and antigen-induced bronchospasms, does not affect spontaneous motor activity, and shows minimal cardiovascular effects in the rat.